Redeye initiates coverage of Guard Therapeutics, a clinical-stage biotech developing innovative therapies for diseases with high unmet needs, focusing on kidney protection at different events of stress. The company is nearing a decisive readout in its phase IIb POINTER study, evaluating RMC-035 as a renal protective agent during cardiac surgery, expected in Q4 2025e. While facing a binary event, we believe the modest valuation offers an asymmetric risk/reward opportunity.
LÄS MER
